Lugano, Switzerland, September 26, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces they are supporting an educational satellite symposium on: “Expanding the options in MF-CTCL: changing the present, shaping the future”. The symposium will be heldat the EORTC CLTF 2018 Annual Meeting in St. Gallen, Switzerland, taking place 27-29 September 2018.
The symposium will take place on Thursday 27 September, 12:45 – 13:45, Hall 9.2, Olma Messen, St Gallen, Switzerland.
This educational symposium will bring together a panel of leading experts in the treatment of Cutaneous Lymphoma, to compare and provide an update on the current treatment options of Mycosis Fungoides Cutaneous T-cell lymphoma (MF-CTCL).
The event will outline the current landscape of MF-CTCL treatment and will provide a better understanding of the planned and ongoing research in this specific area. Moreover, the future of MF-CTCL treatment options will be deeply discussed. This session will also highlight new potential treatment options, as well as research on the mechanism of action of chlormethine.
The full programme for the event is below.
Silvia Sebastiani, Head of Medical Affairs at the Helsinn Group, commented: “Helsinn remains committed to improve the life and well-being of cancer patients. We are delighted to support and bring together this educational symposium to make an overview on the latest research on MF-CTCL, with the final aim of expanding and improving treatments options for patients living with this type of cancer.”
Julia J. Scarisbrick, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, said: “We are very pleased to have the support of the Helsinn Group in bringing together this expert panel at the EORTC annual meeting, and to have put together a stimulating and educational symposium. Over half of CTCL patients are diagnosed with MF-CTCL, and there is no cure for this rare skin cancer. This symposium will be important for the future exploration of treatment options for these patients.”
The full program is available at the following link.
Ledaga® gel is an alkylating drug indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in adult patients. Ledaga® is a gel which is applied topically once a day. The drug has been approved by the European Commission (for MF-CTCL patients in all stages) and received Orphan Drug Designation. It will be commercially available upon completion of Post Authorisation Measures. In France it is provided through an “Autorisation Temporaire d’Utilisation (ATU) de cohort”.
For additional information please see the EU Summary of Product Characteristics.
About Mycosis Fungoides
Mycosis fungoides (MF) accounts for almost 60% of all primary cutaneous T-cell lymphomas, a form of non-Hodgkin’s lymphoma. The cause of MF remains unknown and there are no curative treatments. MF has an indolent clinical course, slowly progressing from patches to thicker plaques and eventually to tumours over years or decades. Signs include rash, patch and plaques with severe itch. MF typically affects older adults (median age at diagnosis: 55-60 years) with male predominance. However, people of all ages can be affected. Depending on the stage and diagnosis at presentation, life expectancy can vary from less than five years after diagnosis to full life expectancy. Evidence from seven global studies (US, n = 4; Europe, n = 3) indicated that the incidence of CTCL has increased over time, reaching ∼10 cases per million individuals per year.
About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco, and China, as well as a product presence in approximately 190 countries globally.
To learn more about Helsinn Group please visit www.helsinn.com
For more information:
Helsinn Group Media Contact
Group Head of Communication
Tel: +41 (0) 91 985 21 21